Mazdutide
Also known as: IBI362, LY3305677, IBI-362, LY-3305677, OXM-3
Classification
Peptide
Regulatory Status
Overview
Mazdutide is described as a dual agonist of the glucagon receptor and the GLP-1 receptor (oxyntomodulin-analog class).
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
ClassB source cannot establish canonical regulatory or safety fields. The statements below are retained as uncertainty, not as a label-backed verdict. | Regulatory status: not-established | Contraindication: Not FDA-approved; not for gray-market self-injection | Warning: GI adverse events (diarrhea, decreased appetite, nausea, vomiting) are common in trials; US product labeling does not exist | Adverse effect: diarrhea | Adverse effect: decreased appetite | Adverse effect: nausea | Adverse effect: vomiting | Serious adverse effect: not fully characterized in a US label
Pathways
Interactions & cautions
Drug interactions
other GLP-1 receptor agonists and insulin/secretagogues — Expected class overlap with incretin therapies (GI effects, glycemic potentiation risk with insulin/secretagogues); no US label interaction table. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.